AZNCF News and Press, AstraZeneca Plc From 01/09/24

2024-01-09 18:04:24 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2024-01-07 07:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The market bounced in ...

2024-01-04 13:51:02 ET More on BioNTech, Moderna, etc. Pfizer: If You Missed The Pandemic Entry, Here's Another Chance BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovatio...

2023-12-31 01:55:00 ET Summary Elpiscience Biopharma forms a $1.7 billion collaboration with Astellas Pharma to develop a bispecific macrophage engager. AstraZeneca acquires Gracell Biotech in a deal worth up to $1.2 billion, including a clinical stage CAR-T therapy. Jinan Qil...

2023-12-27 16:11:16 ET Summary Gracell Biotechnologies has seen a 360% increase in its stock price YTD, with a particular boost since AstraZeneca decided to acquire it for USD $1.2 billion. The acquisition price sounds fair, and the run-up following the announcement leaves little ...

2023-12-26 03:42:42 ET More on AstraZeneca, Gracell Biotechnologies: AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca Pays Hefty Price For Chinese Weight-Loss Drug FDA approves AstraZeneca, Ionis drug for ATTRv-PN Gracell gain...

2023-12-21 13:05:16 ET Summary Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions. ...

2023-12-14 12:25:24 ET Summary Biopharmaceutical sector valuations have become more attractive after a significant decline in 2021. Larger drug companies are making acquisitions and partnerships with small-cap stocks at generous premiums. Money managers are under-invested in t...

2023-12-10 02:15:00 ET Summary Shanghai Abbisko Therapeutics has sold greater China commercialization rights for pimicotinib to Germany's Merck in a $605 million deal. Xtalpi, a China-US AI drug discovery company, has filed for a Hong Kong IPO after raising $780 million in venture...

2023-12-05 22:50:05 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...